inovio.com
DNA immunotherapy targeting hTERT| Inovio
http://www.inovio.com/products/cancer-vaccines/htert
Click here to bypass content and jump to navigation. Immunotherapy for cancers expressing hTERT. Report interim data in 2016. Inovio initiated a phase I clinical trial of its hTERT DNA immunotherapy (INO-1400) in the fourth quarter of 2014. This trial initiation follows positive pre-clinical results, in which Inovio’s hTERT DNA immunotherapy induced strong and broad hTERT-specific CD8 T-cell immune responses in rodents and non-human primates. In 4Q 2014 Inovio initiated a phase I clinical trial of its hT...
inovio.com
DNA Immunotherapy for Prostate Cancer | Inovio
http://www.inovio.com/products/cancer-vaccines/prostate-cancer
Click here to bypass content and jump to navigation. Immunotherapy for prostate cancer. Report interim data 2016. Following strong positive preclinical data, including a simian study in which immunization with INO-5150 generated strong and robust T-cell immune responses, and a murine study in which treatment with INO-5150 induced potent antibody and T-cell responses, Inovio launched a human trial in the third quarter of 2015. INO-5150 prostate cancer immunotherapy. Inovio is testing INO-5150 in a phase I...
inovio.com
Clinical Trials Overview | Inovio
http://www.inovio.com/clinical-trials
Click here to bypass content and jump to navigation. Inovio Pharmaceuticals or its partners and collaborators are conducting multiple clinical trials for DNA immunotherapies to prevent and/or treat cancers and infectious diseases. Inovio may be recruiting for these trials, so please visit the links below for more information. You can find out if you qualify for the study, locations that are available for you, and the length of the trial, along with answers to other frequently asked questions.
inovio.com
Inovio Upcoming and Recent Events
http://www.inovio.com/news/events
Click here to bypass content and jump to navigation. Upcoming and Recent Events. Inovio is presenting at these upcoming scientific, partnering, or investor conferences:. Citi's 11th Annual Biotech Conference. September 7-8, 2016. New York, NY. September 9, 2016. Rodman and Renshaw Annual Global Investment Conference. New York, NY. September 11-13, 2016. 28th Annual Piper Jaffray Healthcare Conference. New York, NY. November 29-30, 2016. 2Q Financial Results Conference Call. August 8, 2016. May 25, 2016.
inovio.com
Inovio – Board of Directors with senior pharmaceutical expertise
http://www.inovio.com/company/leadership/board-of-directors
Click here to bypass content and jump to navigation. Thought leaders in vaccines, DNA vaccines and electroporation with senior pharmaceutical expertise. Avtar Dhillon, M.D. Chairman of the Board, Inovio Pharmaceuticals. Simon X. Benito. Former Senior Vice President, Vaccine Division, Merck. Angel Cabrera, Ph.D. President, George Mason University. Morton Collins, Ph.D. General Partner, Battelle Ventures. J Joseph Kim, Ph.D. President and Chief Executive Officer, Inovio Pharmaceuticals. Professor, Dept....
inovio.com
Inovio’s Synthetic DNA Vaccine Pipeline
http://www.inovio.com/products/pipeline
Click here to bypass content and jump to navigation. Our research and development is focused on applying excellent science to discover and develop potential new synthetic DNA immunotherapies with the goal of creating first-in-class or best-in-class therapeutics and/or preventives. Expect to initiate a phase III clinical trial 2016. First-in-class clinically significant efficacy achieved in controlled phase II study. Cervical cancer HPV Type 16/18. Phase I/II study progressing. Head and neck cancer. PENNV...
inovio.com
Revolutionizing The Fight Against Cancers & Infectious Diseases | Inovio
http://www.inovio.com/company/revolutionizing-vaccines
Click here to bypass content and jump to navigation. Revolutionizing the fight against cancers and infectious diseases. Today, the potential exists to expand the benefits of immune stimulation to overcome cancers. And challenging infectious diseases. With unmet needs; and it is clear which specific technical advancements and medical outcomes must be achieved to fulfill this potential:. There is a need to better define and refine immune system targets in order to induce clinically relevant immune responses.
inovio.com
Inovio’s Advisory Board includes vaccine pioneers
http://www.inovio.com/company/leadership/scientific-advisory-board
Click here to bypass content and jump to navigation. Thought leaders in vaccines, DNA vaccines and electroporation. David B. Weiner, Ph.D. Chairman, Inovio Scientific Advisory Board. Executive Vice President, Director, Vaccine Center. And WW. Smith Endowed Chair in Cancer Research,. Anthony Ford-Hutchinson, Ph.D. Former Senior Vice President, Vaccines R&D, Merck. Stanley A. Plotkin, M.D. Emeritus Professor, Wistar Institute and University of Pennsylvania. Dr Plotkin's numerous professional awards include:.
inovio.com
Inovio - Career Opportunities
http://www.inovio.com/company/careers
Click here to bypass content and jump to navigation. There are hundreds of biotech companies out there. Why should you choose Inovio? Do you want to work with a company on the cutting edge of medical science? Is helping prevent or treat cancers and infectious diseases of the 21st century that are without effective therapies a goal that you would like to work toward? Would you like to be involved in revolutionizing the world of vaccines in order to achieve these goals? Horizontal and diverse hierarchy: We...
inovio.com
Inovio Videos
http://www.inovio.com/resources/video-gallery
Click here to bypass content and jump to navigation. Inovio's Hope For Defeating Cancer. Inovio SynCon Vaccine Design Process. How Inovio's DNA Vaccines Are Delivered. Inovio Rings the Opening Bell. Inovio Scientific Advisors and Board Member Discuss DNA Immunotherapy Potential. Inovio Research Center Building Dedication. Enter Search Keywords and Submit. Inovio In The News. Please enter your email to signup for Inovio news.
